Alzecure Gives Live Streamed Strategy Update on Alzheimer’s Disease and NeuroreStore on September 1
STOCKHOLM, SE / ACCESSWIRE / August 17, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that it will give a live streamed update focusing on its project platform NeuroRestore and Alzheimer's disease on September 1 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Fredrik Thor, analyst at Redeye.
Martin Jönsson, CEO at AlzeCure, together with Johan Sandin, CSO, and Pontus Forsell, Head of Discovery & Research, will present the NeuroRestore platform and the clinical development plan for the company's leading drug candidate ACD856. In addition, Professor Maria Eriksdotter, M.D., PhD, at the Karolinska Institute, will give her view on the neurotrophins BDNF / NGF and potential link to and therapeutic role in Alzheimer's disease.
Watch the livestream on September 1 at 09:00 CEST via:
More information and registration:
The presentation will be held in English.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Maps.me17.9.2021 16:33:43 CEST | Press release
Copper Provides Secure Custody for OXY and MAPS Tokens, Supporting Growing Investor Demand for DeFi
EnviroMetal Technologies Inc.16.9.2021 15:34:59 CEST | Press release
EnviroMetal Technologies Provides Corporate Update
Smart Eye16.9.2021 14:14:59 CEST | Press release
Smart Eye Announces Detlef Wilke as New VP of Automotive Solutions
ITOCO Inc.16.9.2021 13:32:26 CEST | Press release
ITOCO Receives Final Agreement on an Initial 1,014 Hectares of Nopal Cactus Plantations in Mexico for the Purpose of Carbon Credit Capture; and Will Attend "Dia Internacional Del Nopal En Mexico"
Gungnir Resources Inc.15.9.2021 12:02:01 CEST | Press release
Gungnir Drills 21.65 Metres of 1.09% Nickel at Lappvattnet
Biovica International15.9.2021 08:21:46 CEST | Press release
DiviTum(R)TKa Results from SWOG Study Published in Clinical Cancer Research
Biovica International14.9.2021 08:21:37 CEST | Press release
Promising DiviTumTKa Results from BioItaLEE Study Presented at ESMO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom